Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
QURE

QURE - uniQure NV Stock Price, Fair Value and News

8.13USD-0.34 (-4.01%)Delayed as of 18 Jul 2024, 12:05 pm ET

Market Summary

QURE
USD8.13-0.34
Delayedas of 18 Jul 2024, 12:05 pm
-4.01%

QURE Stock Price

View Fullscreen

QURE RSI Chart

QURE Valuation

Market Cap

411.2M

Price/Earnings (Trailing)

-1.39

Price/Sales (Trailing)

21.64

EV/EBITDA

-1.18

Price/Free Cashflow

-3.04

QURE Price/Sales (Trailing)

QURE Profitability

EBT Margin

-1542.31%

Return on Equity

-202.29%

Return on Assets

-38.55%

Free Cashflow Yield

-32.92%

QURE Fundamentals

QURE Revenue

Revenue (TTM)

19.0M

Rev. Growth (Yr)

59.34%

Rev. Growth (Qtr)

26.85%

QURE Earnings

Earnings (TTM)

-296.9M

Earnings Growth (Yr)

15.03%

Earnings Growth (Qtr)

10.37%

Breaking Down QURE Revenue

52 Week Range

8.60
(Low)(High)

Last 7 days

-16.1%

Last 30 days

81.0%

Last 90 days

80.3%

Trailing 12 Months

-20.1%

How does QURE drawdown profile look like?

QURE Financial Health

Current Ratio

9.39

Debt/Equity

0.7

Debt/Cashflow

-1.26

QURE Investor Care

Shares Dilution (1Y)

2.03%

Diluted EPS (TTM)

-6.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202419.0M000
2023108.3M110.1M111.9M15.8M
2022419.6M315.2M210.9M106.5M
2021159.1M280.8M402.4M524.0M
202014.8M22.4M30.0M37.5M
20198.9M8.4M6.3M7.3M
201813.3M11.4M12.3M11.3M
201724.1M24.6M19.7M13.1M
201614.2M17.8M21.5M25.1M
201500010.6M
20140006.1M

Tracking the Latest Insider Buys and Sells of uniQure NV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 26, 2024
abi-saab walid
sold
-6,308
4.36
-1,447
chief medical officer
Jun 19, 2024
meek david d.
acquired
-
-
8,080
-
Jun 19, 2024
post leonard e
acquired
-
-
8,080
-
Jun 19, 2024
kaye jack
acquired
-
-
8,080
-
Jun 19, 2024
springhorn jeremy p.
acquired
-
-
8,080
-
Jun 19, 2024
jacques rachelle suzanne
acquired
-
-
8,080
-
Jun 19, 2024
gut robert
acquired
-
-
8,080
-
Jun 19, 2024
balachandran madhavan
acquired
-
-
8,080
-
Jun 17, 2024
caloz pierre
sold
-14,122
4.81
-2,936
chief operating officer
Jun 17, 2024
klemt christian
sold
-7,732
4.8
-1,611
chief financial officer

1–10 of 50

Which funds bought or sold QURE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 16, 2024
TOTH FINANCIAL ADVISORY CORP
unchanged
-
-118
740
-%
Jul 16, 2024
Future Financial Wealth Managment LLC
sold off
-100
-20,800
-
-%
Jul 12, 2024
SG Americas Securities, LLC
new
-
79,000
79,000
-%
Jul 12, 2024
SANDERS MORRIS HARRIS LLC
unchanged
-
-49,010
304,954
0.05%
Jul 12, 2024
Henry James International Management Inc.
sold off
-100
-205,494
-
-%
Jul 11, 2024
SALEM INVESTMENT COUNSELORS INC
unchanged
-
-216
1,344
-%
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
reduced
-35.59
-11,000
9,000
-%
Jul 09, 2024
HARBOR CAPITAL ADVISORS, INC.
sold off
-100
-181,000
-
-%
Jul 08, 2024
Versant Capital Management, Inc
new
-
609
609
-%
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-562
-
-%

1–10 of 44

Are Funds Buying or Selling QURE?

Are funds buying QURE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own QURE
No. of Funds

Unveiling uniQure NV's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
nantahala capital management, llc
6.6%
3,158,027
SC 13G/A
Feb 13, 2024
vestal point capital, lp
8.2%
3,925,000
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 25, 2024
state street corp
7.28%
3,478,872
SC 13G/A
Oct 06, 2023
blackrock inc.
3.6%
1,731,216
SC 13G/A
Feb 14, 2023
nantahala capital management, llc
8.3%
3,887,939
SC 13G/A
Feb 14, 2023
pfm health sciences, lp
4.9%
6
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
3.6%
1,672,830
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 08, 2023
invesco ltd.
0.5%
219,506
SC 13G/A

Recent SEC filings of uniQure NV

View All Filings
Date Filed Form Type Document
Jul 09, 2024
8-K
Current Report
Jul 01, 2024
8-K
Current Report
Jun 28, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading

Peers (Alternatives to uniQure NV)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
47.5B
6.8B
-10.05% 1.17%
-7.97
6.94
-64.45% -224.75%
30.4B
2.0B
52.57% 15.15%
-91.43
15.16
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.1B
2.5B
-0.42% -1.88%
78.24
6.5
13.74% 186.89%
14.7B
3.8B
4.18% 5.89%
19.67
3.89
8.58% 129.81%
MID-CAP
5.2B
107.9M
2.83% -13.90%
-9.58
48.09
54.84% -28.31%
4.8B
524.1M
-2.08% -1.27%
-11.49
9.15
394.93% 39.61%
4.0B
251.0M
10.21% 12.93%
-13.42
15.84
73.58% -86.73%
3.5B
240.7M
11.63% -19.92%
-7.36
12.77
-1.03% -213.92%
3.0B
813.8M
23.65% -44.38%
-1.8K
3.73
56.43% 98.83%
2.2B
996.6M
12.81% 95.44%
-5.58
2.23
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
12.73% 21.74%
30.67
4.86
60.38% -34.49%
628.7M
881.7K
33.07% 659.10%
-18.62
481.06
-77.61% 33.36%
287.1M
4.2M
23.94% 64.88%
-2.3
69.02
-66.30% 48.24%
18.5M
2.1M
-6.52% -81.14%
-0.8
7.61
-13.45% 69.54%

uniQure NV News

Latest updates
American Banking and Market News11 hours ago
American Banking and Market News16 Jul 202401:36 pm
Simply Wall St12 Jul 202401:12 pm
Benzinga09 Jul 202407:00 am

uniQure NV Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue26.9%8,485,0006,689,0001,407,0002,422,0005,325,000102,745,00051,621,000497,00029,094,00057,691,0001,989,00012,688,00023,387,00034,086,0001,789,0001,535,0002,080,0002,625,0001,046,0002,474,0001,136,000
Costs and Expenses-7.4%63,855,00068,942,00084,480,00068,569,00081,092,00078,235,00062,253,00059,515,00055,990,00058,104,00048,455,00073,224,00045,031,00042,892,00047,091,00039,912,00035,085,00035,170,00032,483,00032,024,00028,604,000
Operating Expenses---------------------28,604,000
  S&GA Expenses-20.3%13,937,00017,488,00018,074,00021,181,00017,848,00018,257,00013,324,00012,491,00010,987,00014,280,00012,023,00017,299,00012,375,00011,208,00010,789,00011,511,0009,072,0008,678,0008,929,0007,870,0008,067,000
  R&D Expenses-4.5%40,692,00042,619,00065,400,00046,036,00060,809,00058,328,00048,068,00046,192,00045,003,00042,026,00036,432,00032,747,00032,656,00031,684,00036,302,00028,401,00026,013,00026,492,00023,554,00024,154,00020,537,000
EBITDA Margin-Infinity%-12.03--1.70-1.47-1.27-1.01-0.51-0.310.820.660.801.09-0.88--------
Interest Expenses2.5%16,097,00015,711,00015,444,0006,840,0003,562,0003,425,5003,069,0002,694,0002,515,0002,097,0001,924,0001,902,0001,551,000938,000942,000970,000975,000956,000960,000937,000957,000
Income Taxes-78.4%656,0003,034,000-69,000163,000-1,207,000-207,000-329,000-318,000-616,000-343,00089,0003,258,000213,000-16,419,000-------
Earnings Before Taxes7.4%-64,962,000-70,172,000-89,640,000-68,311,000-78,434,0006,600,000-48,186,000-39,379,000-47,294,0007,865,000-36,442,000402,726,000-41,343,000-17,118,000-53,775,000-42,551,000-27,999,000-41,426,000-23,604,000-31,399,000-27,772,000
EBT Margin20.3%-15.42-19.35-2.05-1.71-1.47-1.20-0.60-0.370.780.640.771.03---------
Net Income10.4%-65,618,000-73,206,000-89,571,000-68,474,000-77,227,0006,807,000-47,857,000-39,061,000-46,678,0008,208,000-36,531,000399,468,000-41,556,000-699,000-53,775,000-42,551,000-27,999,000-41,426,000-23,604,000-31,399,000-27,772,000
Net Income Margin19.8%-15.62-19.47-2.04-1.70-1.45-1.19-0.59-0.360.770.630.801.08---------
Free Cashflow-22.0%-62,919,000-51,579,00037,211,000-58,071,000-80,644,000-59,746,000-52,976,000-20,257,000-29,769,000-50,643,000-47,851,000414,164,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.4%770832872943631705638701757809775784364340351385414449472253269
  Current Assets-8.6%596652694757443477465523578628594694282259287320350384408189213
    Cash Equivalents0.7%243241229514154231440501525556578677261248279314342381403184209
  Inventory-36.2%8.0012.0016.0010.007.007.004.003.00-------------
  Net PPE-4.3%45.0047.0046.0049.0050.0051.0048.0046.0045.0044.0041.0038.0034.0032.0030.0029.0028.0029.0028.0028.0028.00
  Goodwill-2.2%26.0026.0025.0026.0026.0026.0023.0025.0027.0028.0028.001.001.001.001.000.000.000.000.001.000.00
Liabilities-0.1%62362460358921822921721521121318415113596.00123120119126121121112
  Current Liabilities-13.8%63.0074.0069.0068.0066.0076.0064.0048.0045.0037.0042.0046.0032.0027.0033.0030.0027.0032.0028.0023.0022.00
  Long Term Debt0.4%10210210110110310310210210110171.0071.0070.0036.0035.0035.0036.0036.0036.0036.0036.00
    LT Debt, Non Current0.4%10210210110110310310210210110171.0071.0070.0036.0035.0035.0036.0036.0036.0036.0036.00
Shareholder's Equity-29.3%147208269353413476421486546596591634229244228266295323350132157
  Retained Earnings-7.4%-956-890-817-727-659-581-588-540-501-455-463-426-826-784-784-730-687-659-618-594-563
  Additional Paid-In Capital0.6%1,1561,1491,1421,1311,1221,1131,1001,0921,0841,0771,0691,0621,0501,0161,0071,000992987981733728
Accumulated Depreciation3.8%58.0056.0052.0049.0047.0044.0041.0039.0039.0037.0036.0037.0036.0035.0033.0031.0030.0029.0027.0026.00-
Shares Outstanding1.4%48.0048.0048.0048.0047.0047.0047.0047.0047.0046.0046.0046.00---------
Float----547---870---1,418---2,003---2,957-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-22.3%-60,575-49,54138,911-56,997-78,302-54,680-48,991-15,678-25,711-47,090-40,157416,479-41,273-37,175-34,709-29,991-32,953-26,007-22,020-24,219-26,438
  Share Based Compensation2.1%7,1917,04111,0978,8948,06111,9147,6087,8146,8686,8885,9557,0315,7615,3816,3725,7234,3554,7713,8764,5924,294
Cashflow From Investing7.4%63,98559,562-314,06645,8302,988-168,212-5,063-4,579-4,880-3,553-57,643-2,315-3,876-2,695-2,183-1,716-2,890-1,963-2,256-1,198-1,230
Cashflow From Financing-100.0%-46.00-7,593370,13713160130158.0048529,894-1642,51062,6183,7561392,5391,0101,310244,2905432,678
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

QURE Income Statement

2024-03-31
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenues$ 8,485$ 5,325
Operating expenses:  
Cost of license revenues(150) 
Cost of contract manufacturing revenues(9,076)(2,435)
Research and development expenses(40,692)(60,809)
Selling, general and administrative expenses(13,937)(17,848)
Total operating expenses(63,855)(81,092)
Other income1,3761,811
Other expense(234)(216)
Loss from operations(54,228)(74,172)
Interest income6,5081,669
Interest expense(16,097)(3,562)
Foreign currency losses, net(1,145)(2,369)
Loss before income tax (expense) / benefit(64,962)(78,434)
Income tax (expense) / benefit(656)1,207
Net loss(65,618)(77,227)
Other comprehensive (loss) / income:  
Foreign currency translation (loss) / gains, net(2,524)5,797
Defined benefit pension gain, net of taxes35 
Total comprehensive loss$ (68,107)$ (71,430)
Earnings per ordinary share - basic  
Basic net (loss) / income per ordinary share$ (1.36)$ (1.63)
Earnings per ordinary share - diluted  
Diluted net (loss) / income per ordinary share$ (1.36)$ (1.63)
Weighted average shares - basic48,384,51047,436,335
Weighted average shares - diluted48,384,51047,436,335
License revenues  
Total revenues$ 1,202$ 0
Contract manufacturing revenues  
Total revenues3,9904,937
Collaboration revenues  
Total revenues$ 3,293$ 388

QURE Balance Sheet

2024-03-31
UNAUDITED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 243,062$ 241,360
Current investment securities312,621376,532
Accounts receivable10,7174,193
Inventories, net7,67212,024
Prepaid expenses18,83915,089
Other current assets and receivables3,0922,655
Total current assets596,003651,853
Non-current assets  
Property, plant and equipment, net of accumulated depreciation of $57.8 million as of March 31, 2024 and $55.7 million as of December 31, 202344,55446,548
Operating lease right-of-use assets27,69528,789
Intangible assets, net, including in-process research and development asset of $57.8 million as of March 31, 2024 and $59.1 million as of December 31, 202359,11160,481
Goodwill25,79526,379
Deferred tax assets, net11,59412,276
Other non-current assets5,2985,363
Total non-current assets174,047179,836
Total assets770,050831,689
Current liabilities  
Accounts payable5,2316,586
Accrued expenses and other current liabilities22,65830,534
Current portion of contingent consideration27,58728,211
Current portion of operating lease liabilities7,9978,344
Total current liabilities63,47373,675
Non-current liabilities  
Long-term debt102,120101,749
Liability from royalty financing agreement405,398394,241
Operating lease liabilities, net of current portion26,98328,316
Contingent consideration, net of current portion14,62514,795
Deferred tax liability, net7,3767,543
Other non-current liabilities3,3213,700
Total non-current liabilities559,823550,344
Total liabilities623,296624,019
Commitments and contingencies
Shareholders' equity  
Ordinary shares, €0.05 par value: 80,000,000 shares authorized as of March 31, 2024 and December 31, 2023 and 48,492,357 and 47,833,830 ordinary shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively2,9192,883
Additional paid-in-capital1,155,9041,148,749
Accumulated other comprehensive loss(56,042)(53,553)
Accumulated deficit(956,027)(890,409)
Total shareholders' equity146,754207,670
Total liabilities and shareholders' equity$ 770,050$ 831,689
QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
 CEO
 WEBSITEuniqure.com
 INDUSTRYBiotechnology
 EMPLOYEES501

uniQure NV Frequently Asked Questions


What is the ticker symbol for uniQure NV? What does QURE stand for in stocks?

QURE is the stock ticker symbol of uniQure NV. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of uniQure NV (QURE)?

As of Wed Jul 17 2024, market cap of uniQure NV is 411.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QURE stock?

You can check QURE's fair value in chart for subscribers.

What is the fair value of QURE stock?

You can check QURE's fair value in chart for subscribers. The fair value of uniQure NV is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of uniQure NV is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for QURE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is uniQure NV a good stock to buy?

The fair value guage provides a quick view whether QURE is over valued or under valued. Whether uniQure NV is cheap or expensive depends on the assumptions which impact uniQure NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QURE.

What is uniQure NV's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jul 17 2024, QURE's PE ratio (Price to Earnings) is -1.39 and Price to Sales (PS) ratio is 21.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. QURE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on uniQure NV's stock?

In the past 10 years, uniQure NV has provided -0.029 (multiply by 100 for percentage) rate of return.